The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, comments on the need to bring clinical trials into community settings, as most patients are treated in these environments. Dr Patel highlights the current approach at his institution, which includes the use of data and tools like central screening to identify suitable patients for biomarker-driven therapies and match them with relevant clinical trials. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we know that most patients, especially in the U.S., are treated in the community setting. And we have this mismatch of where clinical trials are, right? They tend to be in very centralized academic centers. So one of the things we recognize is we really have to bring trials into the community. So at SCRI, one of the things we’re able to do is really utilize data to find rare or unusual populations or biomarker-driven therapies into community settings by using data and also using tools like central screening where we can actually at a high level screen a patient, identify that patient for the community oncologist to say hey, this patient’s coming into the clinic, here’s a clinic, here’s a good-looking clinical trial for this patient...
So we know that most patients, especially in the U.S., are treated in the community setting. And we have this mismatch of where clinical trials are, right? They tend to be in very centralized academic centers. So one of the things we recognize is we really have to bring trials into the community. So at SCRI, one of the things we’re able to do is really utilize data to find rare or unusual populations or biomarker-driven therapies into community settings by using data and also using tools like central screening where we can actually at a high level screen a patient, identify that patient for the community oncologist to say hey, this patient’s coming into the clinic, here’s a clinic, here’s a good-looking clinical trial for this patient. So I think these kinds of innovative approaches are really going to help us to unlock the potential for clinical research in the community.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
